David Leffell is a Dermatology physician affiliated with Yale University. OpenAlex indexes 211 publications with 9,139 citations (h-index 39); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Dermatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
40 Temple St
5th Floor, Suite 5a
New Haven, CT 065102715
Telephone
203-785-3466Registry record last updated 13 Feb 2009.
Clinical trials
- Absorbable Suture Versus Tissue Glue to Repair Defects Following Mohs Surgery
Sponsor: Yale University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Validus Pharmaceuticals LLCProgram year20211 payment$10,000openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
37.4%RNA Synthetase Inhibitor Antibacterial37.4%Mupirocin100%Part D≥67 patientsCancer & immunology
29.1%Porphyrin Precursor29.1%Aminolevulinic acid hcl100%Part B, office-administered≥39 patientsAnti-infectives
28.2%First-generation cephalosporins21.8%Cephalexin100%Part D≥41 patientsMacrolide6.3%Erythromycin100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Artificial intelligence in the detection of skin cancer
Journal of the American Academy of Dermatology
2022 - Guidelines of care for the management of actinic keratosis
Journal of the American Academy of Dermatology
2021 - Photodynamic therapy for cutaneous squamous cell carcinoma in situ: Impact of anatomic location, tumor diameter, and incubation time on effectiveness
Journal of the American Academy of Dermatology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
John Krystal, MD
Yale University
Lajos Pusztai, MD
Yale University
Lee Schwamm, MD
Yale University
Naftali Kaminski, MD
Yale University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”